<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>663</serviceExecutionTime><Drug id="86582"><DrugName>RG-7745</DrugName><DrugNamesKey><Name id="43094802">gedivumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>MHAA-4549A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>RG-7745</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>gedivumab</Value><Types><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19453">Genentech Inc</CompanyOriginator><CompaniesSecondary><Company id="19453">Genentech Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="191" type="ciIndication"><TargetEntity id="J09" type="ICD10"></TargetEntity><TargetEntity id="10022000" type="MEDDRA"></TargetEntity><TargetEntity id="D007251" type="MeSH"></TargetEntity><TargetEntity id="948" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3455" type="ciIndication"><TargetEntity id="J09.X" type="ICD10"></TargetEntity><TargetEntity id="863" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="191">Influenza virus infection</Indication><Indication id="3455">Influenza virus A infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="52120">Hemagglutinin modulator</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="168">Monoclonal antibody human</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-03T12:23:40.000Z</LastModificationDate><ChangeDateLast>2018-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2013-07-25T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; was developing RG-7745 (MHAA-4549A), presumed to be gedivumab, a human monoclonal antibody that binds to a highly conserved epitope on the influenza hemagglutinin stalk region, which is designed to neutralize the influenza A virus across a broad range of different strains, for the potential iv treatment of influenza  virus A infection   [&lt;ulink linkID="1440192" linkType="Reference"&gt;1440192&lt;/ulink&gt;], [&lt;ulink linkID="1456571" linkType="Reference"&gt;1456571&lt;/ulink&gt;],   [&lt;ulink linkID="1509368" linkType="Reference"&gt;1509368&lt;/ulink&gt;], [&lt;ulink linkID="1519748" linkType="Reference"&gt;1519748&lt;/ulink&gt;], [&lt;ulink linkID="1520260" linkType="Reference"&gt;1520260&lt;/ulink&gt;],  [&lt;ulink linkID="1519748" linkType="Reference"&gt;1519748&lt;/ulink&gt;], [&lt;ulink linkID="1586607" linkType="Reference"&gt;1586607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, a phase IIa trial began [&lt;ulink linkID="1509368" linkType="Reference"&gt;1509368&lt;/ulink&gt;]; in June 2014, positive data were presented [&lt;ulink linkID="1580367" linkType="Reference"&gt;1580367&lt;/ulink&gt;]. In January 2015, a phase IIb trial of RG-7745 plus &lt;ulink linkID="13460" linkType="Drug"&gt;Tamiflu&lt;/ulink&gt; in hospitalized patients with severe influenza A was initiated  [&lt;ulink linkID="1629535" linkType="Reference"&gt;1629535&lt;/ulink&gt;], [&lt;ulink linkID="1650611" linkType="Reference"&gt;1650611&lt;/ulink&gt;]; the study completed in May 2017  [&lt;ulink linkID="1650611" linkType="Reference"&gt;1650611&lt;/ulink&gt;]. In March 2016, a phase II trial of RG-7745 monotherapy for acute uncomplicated seasonal influenza A started; in October 2017, the trial was expected to complete in November 2017  [&lt;ulink linkID="1753490" linkType="Reference"&gt;1753490&lt;/ulink&gt;]. In April 2015, regulatory submission was planned to be filed post 2018 [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]; in April 2016, filings were expected in 2019 or later  [&lt;ulink linkID="1752925" linkType="Reference"&gt;1752925&lt;/ulink&gt;]. In October 2017, however, Roche reported that the  program had been discontinued [&lt;ulink linkID="1972631" linkType="Reference"&gt;1972631&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2014, the company was planning to file a marketing application after 2017 [&lt;ulink linkID="1519748" linkType="Reference"&gt;1519748&lt;/ulink&gt;]; in April 2015, regulatory submission was planned to be filed post 2018 [&lt;ulink linkID="1653537" linkType="Reference"&gt;1653537&lt;/ulink&gt;]. In April 2016, filings for RG-7745 were expected to be in 2019 or later [&lt;ulink linkID="1752925" linkType="Reference"&gt;1752925&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2016, a randomized, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="247681" linkType="Protocol"&gt;NCT02623322&lt;/ulink&gt;;  GV29893) started to study the safety and efficacy of RG-7745 administered as monotherapy for the treatment of acute uncomplicated seasonal influenza A infection in otherwise healthy adults (estimated n = 141) in the US. At that time, the trial was expected to complete in July 2017. In October 2017, the trial was no longer recruiting and  was expected to be complete in November 2017 [&lt;ulink linkID="1753490" linkType="Reference"&gt;1753490&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2015, the company planned to conduct a phase IIb trial in hospitalized patients requiring oxygen with severe influenza A infection by administering RG-7745 plus &lt;ulink linkID="13460" linkType="Drug"&gt;Tamiflu&lt;/ulink&gt; in one arm and placebo plus Tamiflu in the other arm, to evaluate safety and efficacy [&lt;ulink linkID="1629535" linkType="Reference"&gt;1629535&lt;/ulink&gt;]. The randomized, double-blind trial (&lt;ulink linkID="216321" linkType="Protocol"&gt;NCT02293863&lt;/ulink&gt;; GV29216, 2014-000461-43) began in January 2015 in patients (estimated n = 334), initially in Europe. In April 2015, the study was also enrolling in Korea and New Zealand, and recruitment in Canada, Chile, Peru, Hong Kong, Russian Federation, Singapore, and South Africa was planned. At that time, the trial was expected to complete in February 2017. In October 2016, the recruitment was started in Taiwan. The study completed in May 2017 (n = 168) [&lt;ulink linkID="1650611" linkType="Reference"&gt;1650611&lt;/ulink&gt;].  In April 2018, interim safety and efficacy analysis results from the CRANE study were presented at the 28th ECCMID in Madrid, Spain. Eligible patients (planned n = 330) from 17 countries over 3 Northern and 2 Southern Hemisphere flu seasons were randomized (1:1:1) to receive MHAA-4549A at 3600 mg (iv; low-dose antibody) + oseltamivir, MHAA-4549A at 8400 mg (iv; high-dose antibody) + oseltamivir or placebo iv + oseltamivir. In the placebo, low-dose antibody and high-dose antibody groups, median days to O2 removal was 4.3, 2.8 and 2.7 days; median days to ventilator removal was 4.1, 7.1 and 5.9 days; median days to ICU discharge was 4.7, 6.6 and 5.3 days; and median days to hospital discharge was 9, 7.7 and 6.7 days, respectively. Overall efficacy and safety analysis findings revealed that a numerical trend in deaths and serious adverse events favored the placebo + oseltamivir group [&lt;ulink linkID="2026389" linkType="Reference"&gt;2026389&lt;/ulink&gt;]. In March 2019, pharmacokinetic results were presented at the 2019 ASCPT Annual Meeting in Washington DC. Serum MHAA-4549A concentration appeared to be dose proportional and biphasic, with a mean clearance of 288 to 350 ml/day and mean t1/2 of 17.8 to 19 days, while nasopharyngeal MHAA-4549A concentration was non-dose proportional, with Cmax of 132 to 281 microg/ml   [&lt;ulink linkID="2129050" linkType="Reference"&gt;2129050&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, a randomized, double-blind, placebo-controlled, phase IIa trial (&lt;ulink linkID="161311" linkType="Protocol"&gt;NCT01980966&lt;/ulink&gt;; GV28985, 2013-001983-52) was initiated in the UK to evaluate the safety and efficacy of iv RG-7745 compared to Tamiflu in healthy subjects (expected n = 100) in an influenza challenge model; the trial was expected to be completed in July 2014 [&lt;ulink linkID="1509368" linkType="Reference"&gt;1509368&lt;/ulink&gt;], [&lt;ulink linkID="1520260" linkType="Reference"&gt;1520260&lt;/ulink&gt;]. The study completed in June 2014 [&lt;ulink linkID="1509368" linkType="Reference"&gt;1509368&lt;/ulink&gt;]. In June 2014, data were presented at the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) meeting in Tokyo, Japan; positive results were obtained with 98% reduction of viral load at a 3600-mg dose [&lt;ulink linkID="1580367" linkType="Reference"&gt;1580367&lt;/ulink&gt;]. In September 2015, further clinical data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. RG-7745 showed dose proportional serum pharmacokinetic levels with long terminal half-life (22.5 to 23.7 days) and slow clearance (207 to 240 ml/day). RG-7745 exhibited non-linear nasal pharmacokinetics. Overall, RG-7745 and oseltamivir did not impact the pharmacokinetics of each other [&lt;ulink linkID="1692716" linkType="Reference"&gt;1692716&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2014 a phase I, randomized, double-blind, placebo-controlled study (&lt;ulink linkID="215253" linkType="Protocol"&gt;NCT02284607&lt;/ulink&gt;; GV29609) began to  evaluate the safety, tolerability and pharmacokinetics of two, single iv high doses (8400 or 10,800 mg) of RG-7745  compared to placebo in healthy volunteers (n = 14). At this time the study was expected to complete in March 2015 [&lt;ulink linkID="1696864" linkType="Reference"&gt;1696864&lt;/ulink&gt;]. In September 2015, data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. The percentage of subjects with minor treatment-emergent adverse events (TEAE) were 87.5% for RG-7745 and 83.3% for placebo, with the most common for the drug being headache (n = 4 suspected to be related, n = 3 in the lower dose group). No dose-limiting adverse or serious adverse events were reported and there was no discontinuations; the MTD was not defined. There were no differences in mean values for laboratory values and vital signs from baseline for all doses of RG-7745 compared with placebo. RG-7745 demonstrated linear pharmacokinetics, and no anti- RG-7745 antibodies were detected. The mean terminal half-life for RG-7745 was approximately  21.5 days [&lt;ulink linkID="1694380" linkType="Reference"&gt;1694380&lt;/ulink&gt;], [&lt;ulink linkID="1696821" linkType="Reference"&gt;1696821&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, a randomized, double-blind, placebo-controlled, parallel-assignment, single-ascending-dose, phase I study (&lt;ulink linkID="140211" linkType="Protocol"&gt;NCT01877785&lt;/ulink&gt;; GV28916) of pharmacokinetics and safety was planned to be initiated in July 2013, in healthy volunteers (expected n = 21) in Canada; at that time, the study was expected to complete in November 2013; in July 2013, the trial was initiated [&lt;ulink linkID="1440192" linkType="Reference"&gt;1440192&lt;/ulink&gt;],  [&lt;ulink linkID="1456571" linkType="Reference"&gt;1456571&lt;/ulink&gt;]. Recruitment completed in Q3 2013 (n = 21) [&lt;ulink linkID="1488927" linkType="Reference"&gt;1488927&lt;/ulink&gt;]. In September 2015, data were presented at the 2015 ICAAC/ICC Meeting in San Diego, CA. The percentage of subjects with minor TEAE in the GV28916 study was 62.5% for the RG-7745 arm compared with 60.0% in the placebo arm, with headache and oropharyngeal pain (n = 4 and 2, respectively) being the most common, mostly unrelated to treatment. No dose-limiting adverse or serious adverse events were reported and there was no discontinuations; the MTD was not defined. There were no differences in mean values for laboratory values and vital signs from baseline for all doses compared with placebo. RG-7745 demonstrated linear pharmacokinetics, and no anti- RG-7745 antibodies were detected. The mean terminal half-life for RG-7745 was approximately 23 days. Pharmacokinetics were consistent with human IgG1 antibodies lacking known endogenous targets in humans [&lt;ulink linkID="1694380" linkType="Reference"&gt;1694380&lt;/ulink&gt;], [&lt;ulink linkID="1696821" linkType="Reference"&gt;1696821&lt;/ulink&gt;]. Further clinical data were also presented at the same conference. RG-7745 showed dose proportional serum pharmacokinetic levels with long apparent terminal half-life (21.9 to 24.6 days) and slow clearance (152 to 204 ml/day) [&lt;ulink linkID="1692716" linkType="Reference"&gt;1692716&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2016, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for RG-7745  for the treatment of  influenza [&lt;ulink linkID="1804329" linkType="Reference"&gt;1804329&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="PE">Peru</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2017-10-19T00:00:00.000Z</StatusDate><Source id="1972631" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2013-06-12T00:00:00.000Z</StatusDate><Source id="1440192" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2013-11-05T00:00:00.000Z</StatusDate><Source id="1509368" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="191">Influenza virus infection</Indication><StatusDate>2013-07-25T00:00:00.000Z</StatusDate><Source id="1440192" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2014-01-30T00:00:00.000Z</StatusDate><Source id="1519748" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-01-31T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2014-01-30T00:00:00.000Z</StatusDate><Source id="1519748" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="PE">Peru</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2015-04-07T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2016-10-05T00:00:00.000Z</StatusDate><Source id="1650611" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-09446"><Name>Hemagglutinin</Name><SwissprotNumbers><Swissprot>O11283</Swissprot><Swissprot>O56140</Swissprot><Swissprot>O89746</Swissprot><Swissprot>P03435</Swissprot><Swissprot>P03436</Swissprot><Swissprot>P03437</Swissprot><Swissprot>P03438</Swissprot><Swissprot>P03439</Swissprot><Swissprot>P03440</Swissprot><Swissprot>P03441</Swissprot><Swissprot>P03442</Swissprot><Swissprot>P03443</Swissprot><Swissprot>P03444</Swissprot><Swissprot>P03445</Swissprot><Swissprot>P03446</Swissprot><Swissprot>P03447</Swissprot><Swissprot>P03448</Swissprot><Swissprot>P03449</Swissprot><Swissprot>P03450</Swissprot><Swissprot>P03451</Swissprot><Swissprot>P03452</Swissprot><Swissprot>P03453</Swissprot><Swissprot>P03454</Swissprot><Swissprot>P03455</Swissprot><Swissprot>P03456</Swissprot><Swissprot>P03457</Swissprot><Swissprot>P03458</Swissprot><Swissprot>P03459</Swissprot><Swissprot>P03460</Swissprot><Swissprot>P03461</Swissprot><Swissprot>P03462</Swissprot><Swissprot>P03463</Swissprot><Swissprot>P03464</Swissprot><Swissprot>P04659</Swissprot><Swissprot>P04660</Swissprot><Swissprot>P04661</Swissprot><Swissprot>P04662</Swissprot><Swissprot>P07976</Swissprot><Swissprot>P07977</Swissprot><Swissprot>P09343</Swissprot><Swissprot>P09344</Swissprot><Swissprot>P09345</Swissprot><Swissprot>P09765</Swissprot><Swissprot>P09766</Swissprot><Swissprot>P09767</Swissprot><Swissprot>P10448</Swissprot><Swissprot>P10757</Swissprot><Swissprot>P11132</Swissprot><Swissprot>P11135</Swissprot><Swissprot>P12439</Swissprot><Swissprot>P12440</Swissprot><Swissprot>P12441</Swissprot><Swissprot>P12442</Swissprot><Swissprot>P12443</Swissprot><Swissprot>P12581</Swissprot><Swissprot>P12582</Swissprot><Swissprot>P12583</Swissprot><Swissprot>P12584</Swissprot><Swissprot>P12585</Swissprot><Swissprot>P12586</Swissprot><Swissprot>P12587</Swissprot><Swissprot>P12588</Swissprot><Swissprot>P12589</Swissprot><Swissprot>P12590</Swissprot><Swissprot>P13101</Swissprot><Swissprot>P13102</Swissprot><Swissprot>P13103</Swissprot><Swissprot>P15658</Swissprot><Swissprot>P16060</Swissprot><Swissprot>P16994</Swissprot><Swissprot>P16995</Swissprot><Swissprot>P16996</Swissprot><Swissprot>P16997</Swissprot><Swissprot>P16998</Swissprot><Swissprot>P16999</Swissprot><Swissprot>P17000</Swissprot><Swissprot>P17001</Swissprot><Swissprot>P17002</Swissprot><Swissprot>P17504</Swissprot><Swissprot>P18875</Swissprot><Swissprot>P18876</Swissprot><Swissprot>P19106</Swissprot><Swissprot>P19694</Swissprot><Swissprot>P19695</Swissprot><Swissprot>P19696</Swissprot><Swissprot>P19697</Swissprot><Swissprot>P19698</Swissprot><Swissprot>P19699</Swissprot><Swissprot>P19700</Swissprot><Swissprot>P19701</Swissprot><Swissprot>P19702</Swissprot><Swissprot>P22092</Swissprot><Swissprot>P26094</Swissprot><Swissprot>P26095</Swissprot><Swissprot>P26096</Swissprot><Swissprot>P26097</Swissprot><Swissprot>P26098</Swissprot><Swissprot>P26099</Swissprot><Swissprot>P26100</Swissprot><Swissprot>P26101</Swissprot><Swissprot>P26102</Swissprot><Swissprot>P26103</Swissprot><Swissprot>P26134</Swissprot><Swissprot>P26135</Swissprot><Swissprot>P26136</Swissprot><Swissprot>P26137</Swissprot><Swissprot>P26138</Swissprot><Swissprot>P26139</Swissprot><Swissprot>P26140</Swissprot><Swissprot>P26141</Swissprot><Swissprot>P26562</Swissprot><Swissprot>P28730</Swissprot><Swissprot>P28731</Swissprot><Swissprot>P36346</Swissprot><Swissprot>P43257</Swissprot><Swissprot>P43258</Swissprot><Swissprot>P43259</Swissprot><Swissprot>P43260</Swissprot><Swissprot>P87506</Swissprot><Swissprot>Q03909</Swissprot><Swissprot>Q08011</Swissprot><Swissprot>Q0A3Y1</Swissprot><Swissprot>Q0A448</Swissprot><Swissprot>Q1PUD9</Swissprot><Swissprot>Q2F4V2</Swissprot><Swissprot>Q2ICR0</Swissprot><Swissprot>Q2RCH5</Swissprot><Swissprot>Q2RFA5</Swissprot><Swissprot>Q2VND2</Swissprot><Swissprot>Q2VNF2</Swissprot><Swissprot>Q30NQ1</Swissprot><Swissprot>Q38SQ8</Swissprot><Swissprot>Q67018</Swissprot><Swissprot>Q67143</Swissprot><Swissprot>Q67282</Swissprot><Swissprot>Q67333</Swissprot><Swissprot>Q67369</Swissprot><Swissprot>Q67370</Swissprot><Swissprot>Q67371</Swissprot><Swissprot>Q67372</Swissprot><Swissprot>Q67373</Swissprot><Swissprot>Q67374</Swissprot><Swissprot>Q67375</Swissprot><Swissprot>Q67376</Swissprot><Swissprot>Q67377</Swissprot><Swissprot>Q67378</Swissprot><Swissprot>Q67379</Swissprot><Swissprot>Q67380</Swissprot><Swissprot>Q67381</Swissprot><Swissprot>Q6DPZ9</Swissprot><Swissprot>Q6DQ15</Swissprot><Swissprot>Q6DQ18</Swissprot><Swissprot>Q6DQ19</Swissprot><Swissprot>Q6DQ20</Swissprot><Swissprot>Q6DQ21</Swissprot><Swissprot>Q6DQ22</Swissprot><Swissprot>Q6J8E7</Swissprot><Swissprot>Q6J8F6</Swissprot><Swissprot>Q6LEJ4</Swissprot><Swissprot>Q80A22</Swissprot><Swissprot>Q80A26</Swissprot><Swissprot>Q80A28</Swissprot><Swissprot>Q80A30</Swissprot><Swissprot>Q82509</Swissprot><Swissprot>Q82559</Swissprot><Swissprot>Q8QPL1</Swissprot><Swissprot>Q91MA7</Swissprot><Swissprot>Q9IFF7</Swissprot><Swissprot>Q9Q0U6</Swissprot><Swissprot>Q9WCD8</Swissprot><Swissprot>Q9WCD9</Swissprot><Swissprot>Q9WCE1</Swissprot><Swissprot>Q9WCE3</Swissprot><Swissprot>Q9WCE8</Swissprot><Swissprot>Q9WFX3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2129050" linkType="reference" linkID="2129050"&gt;2129050&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2734583" number="WO-2014078280" title="Enrichment of antigen-specific plasmablasts"/><PatentFamily id="2739893" number="WO-2014078268" title="Anti-hemagglutinin antibodies and methods of use"/><PatentFamily id="2977269" number="WO-2015112994" title="H7N9 influenza a therapies with anti-H7 virus antibodies"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="2">Drug Target</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>